Abstract
There are few original ideas in Science and for that matter in life in general. Most often, such ideas are the “logical extension” of existing knowledge, practice, or state of the art. Originality might be considered as a form of pathology. That is, the incorrect recall or substitution of an idea or act. But it is the ability to recognize new associations which becomes creativity. In these regards, the imperfect mind creates new ideas and a creative mind must be able to sort out what is new or novel. The term “novel”, however, in Science has acquired the connotation of “subject to consideration of patenting”. Most often, novel ideas constituting inventions, are conceived when the time is correct or the circumstances are right and occur independently to more than one person. Hence, the old adage “necessity is the mother of invention”. If such ideas are good enough, those who have conceived them are frequently overshadowed by those who promote them, and originality becomes the victim of promotion or marketing. Good Science is like any other business or human undertaking; the marketing, promotion, and/or propagation of an idea and its application to a useful purpose are all essential components in the inventive process. Otherwise, the best of ideas are soon forgotten.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
S. Magnusson, Thrombin and prothrombin, in: P.D. Boyer, Ed: The Enzymes, 3rd ed, Vol 3, Academic Press, New York, pp. 277 (1971).
S. Magnusson, T.E. Petersen, L. Sottrup-Jensen, and H. Claeys, Complete primary structure of prothrombin: isolation, structure, and reactivity of ten carboxylated glutamic acid residues and regulation of prothrombin activation by thrombin, in: E. Reich, D.B. Rifkin, and E. Shaw, Eds, Proteases and Biological Control, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, pp. 123 (1975).
J.W. Fenton II, B.H. Landis, D.H. Bing, R.D. Feinmann, M.P. Zabinski, S.A. Sonder, L.J. Berliner, and J.S. Finlayson, Human Thrombin: preparative evaluation, structural properties and enzymic specificity, in, D.H. Bing, Ed. The Chemistry and Physiology of the Human Plasma Proteins, Pergamon, New York, NY, pp. 151 (1979).
D.H. Bing, R. Laura, D.J. Robison, B. Furie, B.C. Furie, and R.J. Feldmann, A computer-generated three-dimensional model of the B chain of bovine «thrombin, Ann. NY Acad. Sci, 370: 496 (1981).
J.W. Fenton II, Thrombin specificity, Ann. NY Acad. Sci, 370: 468 (1981).
J.W. Fenton II, and D.H. Bing, Thrombin active-site regions, Semin. Thromb. Hemost, 12: 200 (1986).
B. Furie, D.H. Bing, R.J. Feldmann, D.J. Robison, J.P. Burnier, and B.C. Furie, Computer-generated models of blood coagulation factor Xa, factor IXa, and thrombin based upon structural homology with other serine proteinases, J. Biol. Chem, 57: 3875 (1982).
D.H. Bing, R.J. Feldmann, and J.W. Fenton II, Structure-function relationships of thrombin based on the computer generated three-dimensional model of the B chain of bovine thrombin, Ann. NY Acad. Sci, 485: 104 (1986).
J.W. Fenton II, Thrombin, Ann. NY Acad. Sci, 485: 5 (1986).
J.W. Fenton II, Regulation of thrombin generation and functions, Semin. Thromb. Hemost, 14: 234 (1988).
D. Bagdy, E. Barabas, L. Graf, T.E. Petersen, and S. Magnusson, Hirudin, Methods Enzymol. 45: 669 (1976).
J. Dodt, H.P. Muller, V. Seemuller, and J.Y. Chang, The complete amino acid sequence of hirudin, a thrombin specific inhibitor, FEBS Lett, 165: 180 (1984).
J.Y. Chang, The functional domain of hirudin, a thrombin-specific inhibitor, FEBS Lett, 164: 307 (1984).
J. Dodt, V. Seemuller, R. Maschler, and H. Fritz, The complete covalent structure of hirudin, Localization of the disulfide bonds, Biol. Chem. Hoppe-Seyler, 366: 379 (1985).
J.W. Fenton II, Thrombin interactions with hirudin, Semin. Thromb. Hemost. 15: 265 (1989).
P.H. Johnson, P. Sze, R. Winant, P.W. Payne, and J.B. Lazar, Biochemistry and genetic engineering of hirudin, Semin. Thromb. Hemost. 15: 302 (1989).
W. Bode, I. Mayr, V. Baumann, R. Huber, S.R. Stone, and J. Hofsteenge, The refined 1.9 A crystal structure of human a-thrombin: interaction with D-PhePro-Arg chloromethyl-methyl ketone and significance of the Tyr-Pro-Pro-Trp insertion segment, EMBO J. 8: 3467 (1989).
T.J. Rydel, K.G. Ravichandraw, A. Tulinsky, W. Bode, R. Huber, C. Roitsch, and J.W. Fenton II, The structure of a complex of recombinant hirudin and human «thrombin, Science, 249: 277 (1990).
M.G. Gruther, J.P. Priestle, J. Rahuel, H. Grossenbacher, W. Bode, J. Hofsteenge, and S.R. Stone, Crystal structure of the thrombin-hirudin complex: a novel mode of serine protease inhibition, EMBO J. 9: 2361 (1990).
J.M. Maraganore, P. Bowidon, J. Jablonski, K.L. Ramachandran, and J.W. Fenton II, Design and characterization of hirulogs: a novel class of bivalent peptide inhibitors of thrombin, Biochemistry, 29: 7095 (1990).
J. DiMaio, B. Gibbs, D. Munn, J. Lefebvre, F. Ni, and Y. Konishi, Bifunctional thrombin inhibitors based on the sequence of hirudin45–65, J. Biol. Chem. 265: 21698 (1990).
V.S. Chauhan, Personal communication, 1990.
J.W. Fenton II, T.A. Olson, M.P. Zabinski, and D.G. Wilner, Anion-binding exosite of human a-thrombin and fibrin(ogen) recognition, Biochemistry, 27: 7106 (1988).
J.L. Krstenansky, and S.J. Mao, Antithrombin properties of C-terminus of hirudin using synthetic unsulfated Na-acetyl-hirudin45–65, FEBS Lett. 211: 10 (1987).
S.J.T. Mao, M.T. Yates, T.J. Owen, and J.L. Krstenansky, Interaction of hirudin with thrombin: identification of a minimal binding domain of hirudin that inhibits clotting activity, Biochemistry 27: 8170 (1988).
J.M. Maraganore, B. Chao, M.L. Joseph, J. Jablonski, and K.L. Ramachandran, Anticoagulant activity of synthetic hirudin peptides, J. Biol. Chem. 264: 8692 (1989).
J.W. Fenton II, J.I. Witting, C. Pouliott, and J. Fareed, Thrombin anion-binding exosite interactions with heparin and various polyanions, Ann. NY Acad. Sci. 556: 158 (1989).
J.I. Witting, J.L. Pouliott, J.L. Catalfamo, J. Fareed, and J.W. Fenton II, Thrombin inhibition with dipeptidyl argininals, Thromb. Res. 50: 461 (1988).
C. Kettner, and E. Shaw, D-Phe-Pro-ArgCH2C1 - a selective affinity label for thrombin, Thromb. Res. 14: 969 (1979).
S.A. Sonder, and J.W. Fenton II, Proflavin binding within the fibrinopeptide groove adjacent to the catalytic site of human a-thrombin, Biochemistry 23: 1818 (1984).
J.W. Fenton II, and S.J. Singer, Affinity labelling of antibodies to the p-azophenyltrimethyl-ammonium hapten and a comparison of affinity-labelled antibodies of two different specificities, Biochemistry 10: 1429 (1971).
D.H. Bing, M. Cory, and J.W. Fenton II, Exosite affinity labelling of human thrombin. Similar labelling on the A chain and B chain/fragments of clotting nand nonclotting ß-thrombins, J. Biol. Chem. 252: 3587 (1977).
P. Bourdon, J.W. Fenton II, and J.M. Maraganore, Affinity labelling of lysine-149 in the anion binding exosite of human a-thrombin with a N“-dinitro fluorobenzyl-hirudin C-terminal peptide, Biochemistry 29: 6379 (1990).
J. Dodt, S. Kohler, T. Schmitz, and B. Wilhelm, Distinct binding sites of A1a48hirudinl-47 and A1a48-hirudin48–65 on a-thrombin, J.Biol. Chem. 265: 713 (1990).
J.W. Fenton II, J.I. Witting, P. Bourdon, and J.M. Maraganore, Thrombin-specific inhibition by a novel hirudin analog, Circulation 82:III-659, (abstract) (1990).
J.I. Witting, P. Bourdon, J.M. Maraganore, and J.W. Fenton II, Thrombin-specific inhibition by hirulog-1 and cleavage of its arginyl-3-propyl-4 bond, Thromb. Haemost. 65: 829 (abstract), (1991).
J.M. Maraganore J.W. Fenton II, T. Kline, P. Bourdon, J. Witting, J.A. Jablonski and C. Hammond, Modifications in hirulog peptides yielding improved antithrombin activities, Thromb. Haemost. 65:830 (Abstract).
T. Kline, C. Hammond, P. Bourdon, and J.M. Maraganore, Hirulog peptides with scissile bond replacements resistant to thrombin cleavage, Biochem. Biophys. Res. Commun. 177: 1049 (1991).
F. Ni, H.A. Scheraga, and S.T. Lord, High-resolution NMR studies of fibrinogen-like peptides in solution: resonance assignments and conformational analysis of residues 1–23 of the A« chain of human fibrinogen, Biochemistry 27: 4481 (1988).
F. Ni, Y. Konishi, R.B. Frazier, H.A. Scheraga, and S.T. Lord, High resolution NMR studies of fibrinogen-like peptides in solution: interaction of thrombin with residues 1–23 of the A« chain of human fibrinogen, Biochemistry 28: 3082 (1989).
F. Ni, Y.C. Meinwald, M. Vasquez, and H.A. Scheraga, High-resolution NMRO studies of fibrinogen-like peptides in solution: structure of a thrombin-bound peptide corresponding to residues 7–16 of the A« chain of human fibrinogen, Biochemistry 28: 3094 (1989).
F. Ni, Y. Konishi, L.D. Bullock, M.N. Rivetna, and H.A. Scheraga, High-resolution NMR studies of fibrinogen-like peptides in solution: structural basis for thebleeding disorder caused by a single mutation of Gly12 to Va112 in the A« chain of human fibrinogen Rouen, Biochemistry 28: 3106 (1989).
F. Ni, Y. Konishi, and H.A. Scheraga, Thrombin-bound conformation of the C-terminal fragments of hirudin determined by transferred nuclear Overhauser effects, Biochemistry 29: 4479 (1990).
J. DiMaio, F. Ni, B. Gibbs, and Y. Konishi, A new class of potent thrombin inhibitors that incorporates a scissile pseudopeptide bond, FEBS Lett. 282: 47 (1991).
T. Lindhout, R.Blezer, and H.C. Hemker, The anticoagulant mechanism of action of recombinant hirudin (CGP 39393) in plasma, Thromb. Haemost. 64: 464 (1990).
X.J. Yang, M.A. Blajchman, S. Graven, L.M. Smith, N. Anvari, and F.A. Ofosu, Activation of factor V during intrinsic and extrinsic coagulation. Inhibition by heparin, hirudin and D-Phe-Pro-Arg-CH2Cl, Biochem. J. 272: 399 (1990).
D. Gailani, and G.J. Broze Jr, Factor XI activation in a revised model of blood coagulation, Science 253: 909 (1991).
J.W. Fenton II, G.B. Villaneuva, F.A. Ofosu, and J.M. Maraganore, Thrombin inhibition by hirudin: how hirudin inhibits thrombin, Haemostasis 21 (suppl 1): 27 (1991).
F.A. Ofosu, and J.W. Fenton II, Unpublished data.
J.A. Jakubowski, and J.M. Maraganore, Inhibition of coagulation and thrombin-induced platelet activities by a synthetic dodecapeptide modelled on the carboxy-terminus of hirudin, Blood 75: 399 (1990).
M.A.A. DeMichele, D.G. Moon, J.W. Fenton II, and F.L. Minnear, Thrombin’s enzymatic activity increases permeability of endothelial cell monolayers, J. Appl. Physiol. 69: 1599 (1990).
A. Dawson, P. Loynds, K. Findlen, E. Levin, T. Mant, J. Maraganore, D. Hanson, J. Wagner, and I.Fox, Hirulog-1: a bivalent thrombin inhibitor with potent anticoagulant properties in humans, Thromb. Haemostas. 65: 830 (abstract), (1991).
C. Kettner, L. Mersinger, and R. Knabb R, The selective inhibition of thrombin by peptides of boroarginine, J. Biol. Chem. 265: 18289 (1990).
S. Bajusz, E. Barabas, P. Tolnay, E. Szell, and D. Bagdy, Inhibition of thrombin and trypsin by tripeptide aldehydes, Int. J. Pept. Prot. Res. 12: 217 (1978).
J. Hauptmann, and F. Markwardt, Pharmakologie synthetischer thrombin inhibitoren, Beitrag zur Wirkstoffor-Schung, 26: 1 (1986).
R. Kikumoto, Y. Tamao, T. Tezuka, S. Tonomura, M. Mara, K. Ninomiya, A. Hijikata, and S. Okamoto S, Selective inhibition of thrombin by (2R, 4R)–4methy1–1–1N2–[(3–methyll,2,3,4–tetrahydro–8–quinolinyl) sulfonyl)–L–arginine)12piperidine–carboxylic acid, Biochemistry 23: 85 (1984).
D. Turk, J. Stürzebecher, and W. Bode, Geometry of binding of the No, tosylated piperidides of m-amidino-, p-amidino-and p-guanidino phenylalanine to thrombin and trypsin. X-ray crystal structures of their trypsin complexes and modelling of their thrombin complexes, FEBS Lett. 287: 133 (1991).
S.A. Sonder, and J.W. Fenton II, Thrombin specificity with tripeptide chromo-genic substrates: Comparison of human and bovine thrombins with and without fibrinogen clotting activities, Clin. Chem. 32: 934 (1986).
R. Bar-Shavit, A. Kahn, M.S. Mudd, G.D. Wilner, K.G. Mann, and J.W. Fenton, Localization of a chemotactic domain in human thrombin, Biochemistry 23: 397 (1984).
S.Y. Yue, J. DiMaio, Z. Szewczuk, E.O. Purisima, F. Ni, and Y. Konishi, Characterization of the interactions of a bifunctionalinhibitor with a-thrombin by molecular modelling and peptide synthesis, Protein Engineering 5: 77 (1992).
Z. Szewczuk, D. Leonard, D. Munn, J. DiMaio, F. Ni, S.Y. Yue, and Y. Konishi, Design of thrombin “exo-site” inhibitors based on structure-activity study, Proc. 12th American Peptide Symposium (abstr.) In press.
F. Ni, D.R. Ripoli, and E.O. Purisima, Conformational stability of a thrombin-binding peptide derived from the hirudin C-terminus, Biochemistry 31: 2445 (1992).
N.C. Cohen, J.M. Blaney, C. Humblett, P. Gund, and D.C. Barry, Molecular modelling software and methods for medicinal chemistry, J. Med. Chem. 33: 883 (1990).
F.C. Church, C.W. Pratt, C.N. Noyes, T. Kalayanamit, G.B. Sherill, R.B. Tobin, and J.B. Meade, Structural and functional properties of human a-thrombin, phosphorylated a-thrombin, and Tr-thrombin. Identification of lysyl residues in a-thrombin that are critical for heparin and fibrin(ogen) interactions, J. Biol. Chem. 264: 18419 (1989).
G.L. Hortin, Sulfation of tyrosine residues in coagulation factor V, Blood 76: 946 (1990).
McD. Horne III, and H.R. Gralnick, The oligosaccharide of human thrombin investigations of functional significance, Blood 63: 188 (1984).
T.A. Olson, S.A. Sonder, G.D. Wilner, and J.W. Fenton II, Heparin binding in proximity to the catalytic site of human a-thrombin, Ann. NY Acad. Sci. 485: 96 (1986).
R. Bar-Shavit, V. Sabbah, M.G. Lampugnani, P.C. Marchisio, J.W. Fenton II, I. Vlodaysky, and E. Dejana, An Arg-Gly-Asp sequence within thrombin promotes endothelial cell adhesion, J. Cell. Biol. 112: 335 (1991).
K.C. Glenn, G.H. Frost, J.S. Bergman, and D.H. Carney, Synthetic peptides bind to high-affinity thrombin receptors and modulate thrombin mitogenesis, Peptide Res. 1: 65 (1988).
V.B. Rasmussen, V. Vouret-Craviai, S. Jallat, Y. Schlesinger, G. Pates, A. Pavirani, J.P. Lecoca, J. Pouyssegur, and E. Van Obberghen-Schilling, cDNA cloning and expression of a hamster a-thrombin receptor coupled to Cat+ mobilization, FEBS Lett. 288: 123 (1991).
T.K.H. Vu, D.T. Hung, V.I. Wheaton, and S.R. Coughlin, Molecular cloning of functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation, Cell 64: 1057 (1991).
J.R. Ngaiza, and E.A. Jaffe, A 14 amino acid peptide derived from the amino terminus of the cleaved thrombin receptor elevates intracellular calcium and stimulates prostacyclin production in human endothelial cells. Biochem. Biophys. Res. Commun. 179: 1661 (1991).
A.B. Malik, and J.W. Fenton II, Thrombin-mediated increase in vascular endothelial permeability, Semin. Thromb. Hemost. 18: 193 (1992).
J.W. Fenton II, F.A. Ofosu, D.G. Moon, and J.M. Maraganore, Thrombin structure and function: why thrombin is the primary target for antithrombotics, Blood Coagul. Fibrinol. 2: 69 (1991).
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1993 Springer Science+Business Media New York
About this chapter
Cite this chapter
Fenton, J.W., Ni, F., Witting, J.I., Brezniak, D.V., Andersen, T.T., Malik, A.B. (1993). The Rational Design of Thrombin-Directed Antithrombotics. In: Claeson, G., Scully, M.F., Kakkar, V.V., Deadman, J. (eds) The Design of Synthetic Inhibitors of Thrombin. Advances in Experimental Medicine and Biology, vol 340. Springer, Boston, MA. https://doi.org/10.1007/978-1-4899-2418-6_1
Download citation
DOI: https://doi.org/10.1007/978-1-4899-2418-6_1
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4899-2420-9
Online ISBN: 978-1-4899-2418-6
eBook Packages: Springer Book Archive